Effect of tocilizumab on haematological markers implicates interleukin-6 signalling in the anaemia of rheumatoid arthritis
Open Access
- 1 January 2013
- journal article
- research article
- Published by Springer Science and Business Media LLC in Arthritis Research & Therapy
- Vol. 15 (6), R204
- https://doi.org/10.1186/ar4397
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- Rheumatoid anemiaJoint Bone Spine, 2011
- Iron Sequestration and Anemia of InflammationSeminars in Hematology, 2009
- Interleukin‐6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease‐modifying antirheumatic drugs: The tocilizumab in combination with traditional disease‐modifying antirheumatic drug therapy studyArthritis & Rheumatism, 2008
- Quantification of Hepcidin-25 in Human Serum by Isotope Dilution Micro-HPLC–Tandem Mass SpectrometryClinical Chemistry, 2008
- IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trialAnnals Of The Rheumatic Diseases, 2008
- Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trialThe Lancet, 2008
- Tocilizumab inhibits signal transduction mediated by both mIL-6R and sIL-6R, but not by the receptors of other members of IL-6 cytokine familyInternational Immunopharmacology, 2005
- Time-course analysis of hepcidin, serum iron, and plasma cytokine levels in humans injected with LPSBlood, 2005
- Hepcidin Regulates Cellular Iron Efflux by Binding to Ferroportin and Inducing Its InternalizationScience, 2004
- IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidinJCI Insight, 2004